PTC Therapeutics CEO Stuart Peltz to retire after 25 years

PTC Therapeutics Inc. (PTCT) said that its chief executive officer, Stuart Peltz, will retire. Peltz has led the company as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.

Matthew Klein, current Chief Operating Officer, has been appointed as its CEO and will join the Board of Directors.